Pretreatment Absolute Lymphocyte Count and Neutrophil-to-lymphocyte Ratio Are Prognostic Factors for Stage III Breast Cancer

Anticancer Res. 2021 Jul;41(7):3625-3634. doi: 10.21873/anticanres.15151.

Abstract

Background/aim: Stage III breast cancer comprises a broad spectrum of disease, including the extent of supraclavicular/internal mammary lymph node metastasis. In this study, we evaluated the usefulness of the absolute lymphocyte count (ALC) and neutrophil-to-lymphocyte ratio (NLR) in predicting the prognosis of patients with stage III breast cancer.

Patients and methods: Seventy-five patients with stage III breast cancer who underwent surgery were included. We compared their clinicopathological factors according to the presence or not of supraclavicular/internal mammary lymph node metastasis, and pretreatment ALC or NLR.

Results: Patients with metastasis of the studied lymph nodes had a poorer prognosis in comparison to those without metastasis. In patients without these types of lymph node metastasis, both the ALC and NLR were predictive factors for relapse-free and overall survival. Among these patients, those with a low ALC or high NLR had recurrence-free and overall survival comparable to those of patients with supraclavicular/internal mammary lymph node metastasis.

Conclusion: Pretreatment ALC and NLR were prognostic factors for patients with stage III breast cancer.

Keywords: Breast cancer; lymphocyte; neutrophil.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Breast Neoplasms / pathology*
  • Disease-Free Survival
  • Female
  • Humans
  • Lymph Nodes / pathology
  • Lymphatic Metastasis / pathology
  • Lymphocyte Count / methods
  • Lymphocytes / pathology*
  • Middle Aged
  • Neoplasm Recurrence, Local / pathology
  • Neutrophils / pathology*
  • Prognosis